Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis

Chiao Wen Lin, Wei En Yang, Wei Jiunn Lee, Kuo Tai Hua, Feng Koo Hsieh, Michael Hsiao, Chia Cheng Chen, Jyh Ming Chow, Mu Kuan Chen, Shun Fa Yang, Ming Hsien Chien

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Lipocalin 2 (LCN2), a secreted glycoprotein, is up- or downregulated in different human cancers. At present, the functional role of LCN2 in the progression of oral squamous cell carcinoma (OSCC), which accounts for most head and neck cancers, remains poorly understood, particularly with respect to its involvement in invasion and metastasis. In this study, we observed that LCN2 expression decreased in patients with OSCC and lymph node metastasis compared with that in patients without metastasis. A higher LCN2 expression correlated with the survival of patients with OSCC. Furthermore, LCN2 overexpression in OSCC cells reduced in vitro migration and invasion and in vivo metastasis, whereas its silencing induced an increase in cell motility. Mechanistically, LCN2 inhibited the cell motility of OSCC cells through hypoxia-inducible factor (HIF)-1α-dependent transcriptional inhibition of the carbonic anhydrase IX (CAIX). CAIX overexpression relieved the migration inhibition imposed by LCN2 overexpression in OSCC cells. Moreover, a microRNA (miR) analysis revealed that LCN2 can suppress CAIX expression and cell migration through miR-4505 induction. Examination of tumour tissues from patients with OSCC and OSCC-transplanted mice revealed an inverse correlation between LCN2 and CAIX expression. Furthermore, patients with LCN2strong/CAIXweak revealed the lowest frequency of lymph node metastasis and the longest survival. Our findings suggest that LCN2 suppresses tumour metastasis by targeting the transcriptional and post-transcriptional regulation of CAIX in OSCC cells. LCN2 overexpression may be a novel OSCC treatment strategy and a useful biomarker for predicting OSCC progression.

Original languageEnglish
Pages (from-to)712-722
Number of pages11
JournalCarcinogenesis
Volume37
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Mouth Neoplasms
Squamous Cell Carcinoma
Neoplasm Metastasis
Cell Movement
MicroRNAs
Carbonic Anhydrase IX
Lipocalin-2
Lymph Nodes
Hypoxia-Inducible Factor 1
Cell Hypoxia
Neoplasms
Survival
Head and Neck Neoplasms
Glycoproteins
Down-Regulation
Biomarkers

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research

Cite this

Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis. / Lin, Chiao Wen; Yang, Wei En; Lee, Wei Jiunn; Hua, Kuo Tai; Hsieh, Feng Koo; Hsiao, Michael; Chen, Chia Cheng; Chow, Jyh Ming; Chen, Mu Kuan; Yang, Shun Fa; Chien, Ming Hsien.

In: Carcinogenesis, Vol. 37, No. 7, 01.07.2016, p. 712-722.

Research output: Contribution to journalArticle

Lin, Chiao Wen ; Yang, Wei En ; Lee, Wei Jiunn ; Hua, Kuo Tai ; Hsieh, Feng Koo ; Hsiao, Michael ; Chen, Chia Cheng ; Chow, Jyh Ming ; Chen, Mu Kuan ; Yang, Shun Fa ; Chien, Ming Hsien. / Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis. In: Carcinogenesis. 2016 ; Vol. 37, No. 7. pp. 712-722.
@article{01167c524ba74fadbb23dd88e2e1ca77,
title = "Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis",
abstract = "Lipocalin 2 (LCN2), a secreted glycoprotein, is up- or downregulated in different human cancers. At present, the functional role of LCN2 in the progression of oral squamous cell carcinoma (OSCC), which accounts for most head and neck cancers, remains poorly understood, particularly with respect to its involvement in invasion and metastasis. In this study, we observed that LCN2 expression decreased in patients with OSCC and lymph node metastasis compared with that in patients without metastasis. A higher LCN2 expression correlated with the survival of patients with OSCC. Furthermore, LCN2 overexpression in OSCC cells reduced in vitro migration and invasion and in vivo metastasis, whereas its silencing induced an increase in cell motility. Mechanistically, LCN2 inhibited the cell motility of OSCC cells through hypoxia-inducible factor (HIF)-1α-dependent transcriptional inhibition of the carbonic anhydrase IX (CAIX). CAIX overexpression relieved the migration inhibition imposed by LCN2 overexpression in OSCC cells. Moreover, a microRNA (miR) analysis revealed that LCN2 can suppress CAIX expression and cell migration through miR-4505 induction. Examination of tumour tissues from patients with OSCC and OSCC-transplanted mice revealed an inverse correlation between LCN2 and CAIX expression. Furthermore, patients with LCN2strong/CAIXweak revealed the lowest frequency of lymph node metastasis and the longest survival. Our findings suggest that LCN2 suppresses tumour metastasis by targeting the transcriptional and post-transcriptional regulation of CAIX in OSCC cells. LCN2 overexpression may be a novel OSCC treatment strategy and a useful biomarker for predicting OSCC progression.",
author = "Lin, {Chiao Wen} and Yang, {Wei En} and Lee, {Wei Jiunn} and Hua, {Kuo Tai} and Hsieh, {Feng Koo} and Michael Hsiao and Chen, {Chia Cheng} and Chow, {Jyh Ming} and Chen, {Mu Kuan} and Yang, {Shun Fa} and Chien, {Ming Hsien}",
year = "2016",
month = "7",
day = "1",
doi = "10.1093/carcin/bgw050",
language = "English",
volume = "37",
pages = "712--722",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis

AU - Lin, Chiao Wen

AU - Yang, Wei En

AU - Lee, Wei Jiunn

AU - Hua, Kuo Tai

AU - Hsieh, Feng Koo

AU - Hsiao, Michael

AU - Chen, Chia Cheng

AU - Chow, Jyh Ming

AU - Chen, Mu Kuan

AU - Yang, Shun Fa

AU - Chien, Ming Hsien

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Lipocalin 2 (LCN2), a secreted glycoprotein, is up- or downregulated in different human cancers. At present, the functional role of LCN2 in the progression of oral squamous cell carcinoma (OSCC), which accounts for most head and neck cancers, remains poorly understood, particularly with respect to its involvement in invasion and metastasis. In this study, we observed that LCN2 expression decreased in patients with OSCC and lymph node metastasis compared with that in patients without metastasis. A higher LCN2 expression correlated with the survival of patients with OSCC. Furthermore, LCN2 overexpression in OSCC cells reduced in vitro migration and invasion and in vivo metastasis, whereas its silencing induced an increase in cell motility. Mechanistically, LCN2 inhibited the cell motility of OSCC cells through hypoxia-inducible factor (HIF)-1α-dependent transcriptional inhibition of the carbonic anhydrase IX (CAIX). CAIX overexpression relieved the migration inhibition imposed by LCN2 overexpression in OSCC cells. Moreover, a microRNA (miR) analysis revealed that LCN2 can suppress CAIX expression and cell migration through miR-4505 induction. Examination of tumour tissues from patients with OSCC and OSCC-transplanted mice revealed an inverse correlation between LCN2 and CAIX expression. Furthermore, patients with LCN2strong/CAIXweak revealed the lowest frequency of lymph node metastasis and the longest survival. Our findings suggest that LCN2 suppresses tumour metastasis by targeting the transcriptional and post-transcriptional regulation of CAIX in OSCC cells. LCN2 overexpression may be a novel OSCC treatment strategy and a useful biomarker for predicting OSCC progression.

AB - Lipocalin 2 (LCN2), a secreted glycoprotein, is up- or downregulated in different human cancers. At present, the functional role of LCN2 in the progression of oral squamous cell carcinoma (OSCC), which accounts for most head and neck cancers, remains poorly understood, particularly with respect to its involvement in invasion and metastasis. In this study, we observed that LCN2 expression decreased in patients with OSCC and lymph node metastasis compared with that in patients without metastasis. A higher LCN2 expression correlated with the survival of patients with OSCC. Furthermore, LCN2 overexpression in OSCC cells reduced in vitro migration and invasion and in vivo metastasis, whereas its silencing induced an increase in cell motility. Mechanistically, LCN2 inhibited the cell motility of OSCC cells through hypoxia-inducible factor (HIF)-1α-dependent transcriptional inhibition of the carbonic anhydrase IX (CAIX). CAIX overexpression relieved the migration inhibition imposed by LCN2 overexpression in OSCC cells. Moreover, a microRNA (miR) analysis revealed that LCN2 can suppress CAIX expression and cell migration through miR-4505 induction. Examination of tumour tissues from patients with OSCC and OSCC-transplanted mice revealed an inverse correlation between LCN2 and CAIX expression. Furthermore, patients with LCN2strong/CAIXweak revealed the lowest frequency of lymph node metastasis and the longest survival. Our findings suggest that LCN2 suppresses tumour metastasis by targeting the transcriptional and post-transcriptional regulation of CAIX in OSCC cells. LCN2 overexpression may be a novel OSCC treatment strategy and a useful biomarker for predicting OSCC progression.

UR - http://www.scopus.com/inward/record.url?scp=84978696474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978696474&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgw050

DO - 10.1093/carcin/bgw050

M3 - Article

VL - 37

SP - 712

EP - 722

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 7

ER -